After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Other U.S. multinationals could also face hefty back-tax bills.
It took 12 months for Teva to gain FTC approval to buy Allergan's U.S. generics business. Future mergers could face the same long scrutiny.
The going has been a bit tough for David Einhorn lately, and he has been doing some selling in turn.
The deal could be worth $1.5 billion.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.